Evidence map›Paper›PMID 24843375›Full record

ArticlePsychiatry investigation2014

A Disrupted-in-Schizophrenia 1 Gene Variant is Associated with Clinical Symptomatology in Patients with First-Episode Psychosis.

Javier Vázquez-Bourgon, Ignacio Mata, Roberto Roiz-Santiáñez, Rosa Ayesa-Arriola, Paula Suárez Pinilla, Diana Tordesillas-Gutiérrez, José Luis Vázquez-Barquero, Benedicto Crespo-Facorro

Open access · diamondAbstract read
In one paragraph

Article in Psychiatry investigation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Differential Association of theInternational journal of molecular sciences · 2025
    Article
  2. Markers of Schizophrenia-A Critical Narrative Update.Journal of clinical medicine · 2022
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Javier Vázquez-BourgonDepartment of Psychiatry, University Hospital Marques de Valdecilla-IFIMAV, School of Medicine, University of Cantabria, Santander, Spain. ; Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
Ignacio MataCentro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
Roberto Roiz-SantiáñezDepartment of Psychiatry, University Hospital Marques de Valdecilla-IFIMAV, School of Medicine, University of Cantabria, Santander, Spain. ; Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
Rosa Ayesa-ArriolaDepartment of Psychiatry, University Hospital Marques de Valdecilla-IFIMAV, School of Medicine, University of Cantabria, Santander, Spain. ; Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
Paula Suárez PinillaDepartment of Psychiatry, University Hospital Marques de Valdecilla-IFIMAV, School of Medicine, University of Cantabria, Santander, Spain.
Diana Tordesillas-GutiérrezDepartment of Psychiatry, University Hospital Marques de Valdecilla-IFIMAV, School of Medicine, University of Cantabria, Santander, Spain. ; Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
José Luis Vázquez-BarqueroDepartment of Psychiatry, University Hospital Marques de Valdecilla-IFIMAV, School of Medicine, University of Cantabria, Santander, Spain. ; Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
Benedicto Crespo-FacorroDepartment of Psychiatry, University Hospital Marques de Valdecilla-IFIMAV, School of Medicine, University of Cantabria, Santander, Spain. ; Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
Centro de Investigación Biomédica en Red de Salud Mental · ESUniversidad de Cantabria · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDISC1 gene is one of the main candidate genes for schizophrenia since it has been associated to the illness in several populations. Moreover, variations in several DISC1 polymorphisms, and in particular Ser704Cys SNP, have been associated in schizophrenic patients to structural and functional modifications in two brain areas (pre-frontal cortex and hippocampus) that play a central role in the genesis of psychotic symptoms. This study tested the association between Ser704Cys DISC1 polymorphism and the clinical onset of psychosis.

methodsTwo hundred and thirteen Caucasian drug-naive patients experiencing a first episode of non-affective psychosis were genotyped for rs821616 (Ser704Cys) SNP of the DISC1 gene. The clinical severity of the illness was assessed using SAPS and SANS scales. Other clinical and socio-demographic variables were recorded to rule out possible confounding effects.

resultsPatients homozygous for the Ser allele of the Ser704Cys DISC1 SNP had significantly (p<0.05) higher rates at the positive symptoms dimension (SAPS-SANS scales) and hallucinations item, compared to Cys carriers.

conclusionDISC1 gene variations may modulate the clinical severity of the psychosis at the onset of the disorder.

Indexed as

DISC1 ser704cysGeneticsHallucinationsSchizophreniaSeverity of illness

Identifiers

PMID24843375
PMCPMC4023094
OpenAlexW2129301819

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.